Tower Research Capital (TRC)’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-3,086
| Closed | -$17.5K | – | 5531 |
|
|
2025
Q3 | $17.5K | Sell |
3,086
-6,238
| -67% | -$31.9K | ﹤0.01% | 3425 |
|
|
2025
Q2 | $35.5K | Buy |
9,324
+5,473
| +142% | +$17K | ﹤0.01% | 3266 |
|
|
2025
Q1 | $10.1K | Buy |
3,851
+338
| +10% | +$1.1K | ﹤0.01% | 3673 |
|
|
2024
Q4 | $12.4K | Sell |
3,513
-474
| -12% | -$1.82K | ﹤0.01% | 3616 |
|
|
2024
Q3 | $18.2K | Sell |
3,987
-3,143
| -44% | -$15.2K | ﹤0.01% | 3289 |
|
|
2024
Q2 | $31K | Sell |
7,130
-3,525
| -33% | -$15.5K | ﹤0.01% | 3466 |
|
|
2024
Q1 | $53.5K | Buy |
10,655
+5,137
| +93% | +$28.8K | ﹤0.01% | 2228 |
|
|
2023
Q4 | $34.6K | Sell |
5,518
-6,472
| -54% | -$37.1K | ﹤0.01% | 3346 |
|
|
2023
Q3 | $85.4K | Buy |
11,990
+11,285
| +1,601% | +$88.9K | ﹤0.01% | 2095 |
|
|
2023
Q2 | $7.18K | Sell |
705
-16,277
| -96% | -$170K | ﹤0.01% | 4611 |
|
|
2023
Q1 | $154K | Buy |
16,982
+2,533
| +18% | +$18.6K | ﹤0.01% | 1520 |
|
|
2022
Q4 | $104K | Buy |
14,449
+6,433
| +80% | +$39.3K | ﹤0.01% | 1810 |
|
|
2022
Q3 | $52K | Buy |
8,016
+1,520
| +23% | +$8.12K | ﹤0.01% | 3135 |
|
|
2022
Q2 | $31K | Buy |
6,496
+6,396
| +6,396% | +$31.7K | ﹤0.01% | 3350 |
|
|
2022
Q1 | $1K | Buy |
+100
| New | +$491 | ﹤0.01% | 5851 |
|
|
2021
Q3 | – | Sell |
-2,112
| Closed | -$13K | – | 6124 |
|
|
2021
Q2 | $13K | Sell |
2,112
-621
| -23% | -$3.75K | ﹤0.01% | 4235 |
|
|
2021
Q1 | $18K | Sell |
2,733
-807
| -23% | -$5.53K | ﹤0.01% | 3968 |
|
|
2020
Q4 | $19K | Sell |
3,540
-2,015
| -36% | -$15.8K | ﹤0.01% | 3905 |
|
|
2020
Q3 | $41K | Sell |
5,555
-5,685
| -51% | -$44.4K | ﹤0.01% | 3619 |
|
|
2020
Q2 | $83K | Buy |
11,240
+9,639
| +602% | +$84.7K | ﹤0.01% | 2627 |
|
|
2020
Q1 | $12K | Buy |
1,601
+964
| +151% | +$6.99K | ﹤0.01% | 1946 |
|
|
2019
Q4 | $4K | Buy |
+637
| New | +$3.26K | ﹤0.01% | 2815 |
|
|
2019
Q3 | – | Sell |
-3,211
| Closed | -$10K | – | 4471 |
|
|
2019
Q2 | $10K | Sell |
3,211
-4,235
| -57% | -$13.9K | ﹤0.01% | 2576 |
|
|
2019
Q1 | $22K | Buy |
7,446
+6,420
| +626% | +$22K | ﹤0.01% | 2221 |
|
|
2018
Q4 | $4K | Buy |
1,026
+751
| +273% | +$3.53K | ﹤0.01% | 3064 |
|
|
2018
Q3 | $2K | Sell |
275
-1,155
| -81% | -$5.88K | ﹤0.01% | 3475 |
|
|
2018
Q2 | $8K | Buy |
+1,430
| New | +$14.7K | ﹤0.01% | 2891 |
|
Tower Research Capital (TRC)'s SCPH Position: Q4 2025 in Review
Tower Research Capital (TRC) sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 3,086 shares — an estimated $17.5K sold.
Tower Research Capital (TRC) first reported a position in SCPH in Q2 2018 and held it in 27 quarters. The position peaked at $154K in Q1 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- Tower Research Capital (TRC) reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,086 scPharmaceuticals shares in Q4 2025, an estimated $17.5K.
- Tower Research Capital (TRC) first reported a position in scPharmaceuticals in Q2 2018 and held it in 27 quarters.
- Tower Research Capital (TRC)'s scPharmaceuticals position peaked at $154K in Q1 2023.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.